Skip to content
Diabetes
-
-
-
-
-
-
-
Novo Nordisk phases out Levemir in the U.S. amidst growing insulin pricing pressure
USA — Novo Nordisk, a major player in the pharmaceutical industry, has announced plans to discontinue its long-acting insulin treatment, Levemir, in the U.S. by…
-
FDA greenlights Eli Lilly’s Zepbound: A game-changer in weight loss medication landscape
USA — The Food and Drug Administration (FDA) has granted approval to Eli Lilly’s Zepbound, a potent medication for weight loss targeting adults grappling with…
-
Novo Nordisk expands innovative approaches to tackle obesity and Type 2 diabetes
DENMARK — Novo Nordisk, renowned for its successful pharmaceuticals like Ozempic, Wegovy, Victoza, and Saxenda, is diversifying its strategies in the realm of obesity and…
-
Eli Lilly resolves Mounjaro supply issues, continues expansion amid surging demand
USA — Eli Lilly has reported improvements in the supply of its popular diabetes drug, Mounjaro, in the U.S. after facing months of widespread shortages.…